<DOC>
	<DOCNO>NCT01650558</DOCNO>
	<brief_summary>The purpose study determine benefit take trimethoprim-sulfamethoxazole ( TS ) prophylaxis among HIV positive adult viral load suppression good clinical response anti-retroviral therapy ( ART ) . If benefit , due antimalarial antibacterial property . The investigator hypothesize long-term benefit survival disease control context prophylaxis benefit largely attributed prevention malaria . The main study hypothesis 1 ) TS chloroquine ( CQ ) decrease rate morbidity mortality among adult 6 month ART 2 ) CQ prophylaxis associate prolonged viral suppression high CD4 cell count TS prophylaxis prophylaxis .</brief_summary>
	<brief_title>Daily Trimethoprim-sulfamethoxazole Weekly Chloroquine Among Adults ART Malawi</brief_title>
	<detailed_description>This randomize , control , open-label , phase III trial standard care TS prophylaxis CQ prophylaxis compare prophylaxis adult receive ART . Adults receive ART least six month good clinical response provide inform consent fulfill eligibility criterion randomize one three arm : ( 1 ) continue standard care trimethoprim-sulfamethoxazole ( TS ) prophylaxis , ( 2 ) discontinue standard care TS prophylaxis begin weekly CQ prophylaxis ( 3 ) discontinue standard care TS prophylaxis . Participants ask return research clinic every four week first 24 week every 12 week thereafter , time ill facilitate active passive follow-up study endpoint . Participation last 32 approximately 66 month . Participants develop WHO clinical stage 3 4 illness , experience sustain decline CD4 count 200 cells/mm3 , experience ART failure place standard care TS prophylaxis . Those confirmed ART failure evaluate second-line therapy accord Malawi Ministry Health guideline . The study population include 1500 Malawian adult age 18 year old live HIV near Blantyre Zomba , Malawi , Central Africa receive antiretroviral therapy least 6 month good clinical response ART , undetectable HIV viral load CD4 count &gt; 250/mm3 .</detailed_description>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>Age 18 year older Documented HIV1 infection Initiation ART governmentsponsored ART program least six month prior Undetectable HIV viral load ( &lt; 400 copies/mL ) CD4 count &gt; 250/mm3 TS prophylaxis prescribe least previous 2 month Intention remain study area end study period Informed consent participant Female study volunteer reproductive potential must negative urine pregnancy test perform within 20 day randomization . Female study volunteer reproductive potential participate sexual activity could lead pregnancy must use contraception ( male female condom , diaphragm cervical cap spermicide , intrauterine device , hormonebased contraceptive ) receiving assign study drug one month stop medication . Severe acute illness ( define require hospitalization time screen condition laboratory abnormality determine investigator ) Chronic treatment ( require therapy &gt; 14 day ) secondary prophylaxis ( toxoplasmosis , Pneumocystis pneumonia , tuberculosis example ) drug antimalarial antibacterial activity History hypersensitivity antifolate drug CQ Laboratory exclusion criterion Hemoglobin &lt; 8.0 gm/dL Platelet count &lt; 50,000/mm3 Absolute granulocyte count &lt; 500/mm3 Serum alanine aminotransferase ( ALT ) concentration &gt; 210 U/L men , &gt; 160 U/L woman Serum creatinine concentration &gt; 3.3mg/dl ( 291.7µmol/L ) men , &gt; 2.7mg/dl ( 238.7µmol/L ) woman ) History visual field retinal change History preexist auditory damage History porphyria History psoriasis History liver disease History seizure disorder History glucose6phosphate dehydrogenase ( G6PD ) deficiency History ECG cardiac conduction abnormality cardiomyopathy History myopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Malaria</keyword>
	<keyword>HIV</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Antiretroviral therapy</keyword>
</DOC>